NCT06118931Recruiting
Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
The Impact of Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 123 (estimated)
- First submitted
- 31 Oct 2023
- Start date
- 28 Jun 2025
- Primary completion date
- 28 Jun 2027
- Lead sponsor
- University of Toronto
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06118931
What you commit to
- Study type: Interventional
- Planned participants: 123
- From 28 Jun 2025 to the primary completion date, 28 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The following exclusion criteria applies to all potential participants:
- History of or referral for bariatric surgery
- Weight loss \>3% in the last 3 months
- Taking antiobesity (weight loss) medications
- Body weight \>390lbs
- Diagnosed with severe cognitive disorder that precludes them from giving consent
- Inability or unwillingness to change their eating window to follow those prescribed in the study
- Currently consistently eating during \<11.5 hour period .
- Physician-diagnosed eating disorder
- Having a pacemaker or receiving dialysis.
- Not having access to a Lifelabs location.
Lab values
- Individuals with type 2 diabetes will be excluded if: (1) currently on \>2 monotherapies for diabetes, (2) have had diabetes therapy medication or dosage changes \<3 months, (3) self-reported hemoglobin A1c \>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas
Who the study is looking for
- Aged 40 years or older
- Body mass index \<50 kg/m2
- Have access to an Apple or Android cellphone with Bluetooth.
- Have type 2 diabetes or be at risk for type 2 diabetes (defined as self-report of pre-diabetes, a recent (within 12 months) measure of HbA1c between 5.7 and 6.4%, waist circumference (WC) that is BMI specific; for women: BMI \>= 18.5-24.9, WC \>= 80cm; BMI \>= 25-29.9, WC \>= 90cm; BMI \>= 30-34.9, WC \>= 105cm; BMI \>= 35+, WC \>= 115cm; for men: BMI \>= 18.5-24.9, WC \>= 90cm; BMI \>= 25-29.9, WC \>= 100cm; BMI \>= 30-34.9, WC \>= 110cm; BMI \>= 35+, WC \>= 125cm.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Remote Ontario-wide Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.